Released Nov 14, 2025, during market hours
10-Q filed Nov 14, 2025, 45 days after period end · 0000926617-25-000008
Q3 2025 · 10-Q
Revenue$2.31M$2.31M +2.1% vs Q3 2024−4.1% vs Q2 2025
Net Income-$4.89M-$4.89M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.13-$0.13 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$1,383,000+2.1%
Operating Income-$1,579,000N/M
Operating Cash Flowderived-$212,000N/M
Margins · derived
Gross margin60.0%−0.0 pt vs Q3 2024
Operating margin-68.5%+97.4 pt vs Q3 2024
Net margin-212.2%−55.1 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $2.31M | $2.26M | $2.22M | $2.07M |
| Net Income | -$4.89M | -$3.55M | -$4.71M | -$7.78M |
| EPS Diluted | -$0.13 | -$0.23 | -$0.48 | -$1.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aspira Women's Health Inc. · CIK 926617 · Engraved from SEC EDGAR